Corvus Pharmaceuticals (CRVS) Return on Capital Employed (2016 - 2026)
Corvus Pharmaceuticals (CRVS) recorded quarterly Return on Capital Employed of 31.94% in Q1 2026, up 50.63% quarter-over-quarter from 64.7% in Q4 2025, and up 2493.0% on a YoY basis from 1.23% in Q1 2025.
Corvus Pharmaceuticals (CRVS) Return on Capital Employed (2016 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Return on Capital Employed history runs 11 years deep, the most recent figure standing at 31.94% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 2493.0% year-over-year to 31.94%; the TTM figure through Mar 2026 stood at 31.94% (up 2493.0% YoY), while the FY2025 annual figure was 70.87%, up 5533.0% from the prior year.
- Return on Capital Employed was 31.94% for Q1 2026 at Corvus Pharmaceuticals, up from 64.7% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 31.94% in Q1 2026 to a low of 164.21% in Q3 2024.
- Historically, Return on Capital Employed has averaged 60.86% across 5 years, with a median of 55.89% in 2023.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed tumbled 11510 bps in 2024, then jumped 11367 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 51.25% in 2022, then decreased by 9 bps to 55.89% in 2023, then sank by 73 bps to 96.8% in 2024, then soared by 33 bps to 64.7% in 2025, then soared by 51 bps to 31.94% in 2026.
- The last three Return on Capital Employed figures came in at 31.94% (Q1 2026), 64.7% (Q4 2025), and 50.54% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -107.40% |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -50.43% |
| 10 | Corvus Pharmaceuticals | 1.00 Bn | 766.75 Mn | - | -31.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -31.94% |
| Dec 31, 2025 | -64.70% |
| Sep 30, 2025 | -50.54% |
| Jun 30, 2025 | -53.90% |
| Mar 31, 2025 | -56.87% |
| Dec 31, 2024 | -96.80% |
| Sep 30, 2024 | -164.21% |
| Jun 30, 2024 | -60.02% |
| Mar 31, 2024 | -63.95% |
| Dec 31, 2023 | -55.89% |
| Sep 30, 2023 | -49.11% |
| Jun 30, 2023 | -60.35% |
| Mar 31, 2023 | -57.76% |
| Dec 31, 2022 | -51.25% |
| Sep 30, 2022 | -46.52% |
| Jun 30, 2022 | -34.90% |
| Mar 31, 2022 | -35.96% |
| Dec 31, 2021 | -36.90% |
| Sep 30, 2021 | -40.46% |
| Jun 30, 2021 | -43.83% |